Inovio Biomedical to Present at International DNA Vaccine Conference
|
|
|
| Posted
:
Mon, 06 Jul 2009 07:00:52 GMT |
| Author
:
Inovio Biomedical Corporation
|
| Category
:
Press Release |
| News Alerts by
Email ( click
here ) |
| Press Release
News |
Home
|
|
|
|
SAN DIEGO - (Business Wire) Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that it will make multiple presentations at the Annual Conference of DNA Vaccines in Asia 2009 being hosted by the International Society of DNA Vaccines July 9 – 10 at the Beijing International Convention Center. The conference, with the theme, “Advancing DNA Vaccine Technology,” is co-chaired by David B. Weiner, Ph.D., professor of pathology, University of Pennsylvania School of Medicine, and chairman of Inovio’s scientific advisory board. Inovio scientists and associates will be making the following presentations: | Engineering Highly Immune Potent DNA Vaccines by Engineering Molecular Biology, Immunology and Physical Delivery In Vivo | | Presidential Address and Keynote Lecture | | David B. Weiner, Ph.D. | | Thursday July 9 | | 08:30 - 09:05 | | Location: 305BC | | | | Immune Therapy by Electroporation | | Plenary Session 2 | | Iacob Mathiesen, Ph.D., Managing Director, Inovio AS | | Thursday July 9 | | 11:00 - 12:10 | | Location: 305BC | | | | Pandemic and Seasonal Influenza DNA Vaccines Delivered via Electroporation | | Plenary Session 3 | | Niranjan Y. Sardesai, Ph.D., Sr. VP, Research & Development, Inovio Biomedical | | Thursday July 9 | | 13:10 - 14:55 | | Location: 305BC | | | | Special Considerations for Multi-Component DNA Vaccine Production | | Plenary Session 7 | | Henry Hebel, Chief Operating Officer, VGXI Inc. | | Friday July 10 | | 11:00 - 12:10 | | Location: 305BC | | | About Inovio Biomedical Corporation Inovio Biomedical is engaged in the design, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The company’s SynCon™ technology enables the design of DNA-based vaccines capable of providing cross-protection against evolving, unmatched strains of pathogens such as influenza. Inovio’s proprietary electroporation-based DNA vaccine delivery technology has been shown by initial human data to safely and significantly increase gene expression and immune responses. Inovio’s clinical programs include HPV/cervical cancer (therapeutic) and HIV vaccines. An IND has been filed for an avian influenza vaccine. Partners and collaborators include Merck, Tripep, University of Southampton, University of Pennsylvania, and HIV Vaccines Trial Network. Inovio’s product candidates and technologies are protected by an extensive global intellectual property portfolio. More information is available at www.inovio.com. This press release contains certain forward-looking statements relating to our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications and that results from one study may not necessarily be reflected or supported by the results of other similar studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the parties or their collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the parties and their collaborators hope to develop, evaluation of potential opportunities, issues involving patents and whether they or licenses to them will provide the parties with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the combined company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the companies’ combined technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals, our ability to maintain listing of our common stock under the rules and regulations of the NYSE Amex and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2008, our Form 10-Q for the three months ended March 31, 2009, and other regulatory filings from time to time, including our current report on Form 8-K reporting the closing of the merger transaction with VGX Pharmaceuticals, Inc. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate. Inovio Biomedical Bernie Hertel, 858-410-3101 (Investors) or Richardson & Associates Jeff Richardson, 805-491-8313 (Media)
|

Copyright © 2008
Business Wire. All rights reserved.
|
|
|
|
|
Related
News
Pixman Updates on Filing of Annual Financial Statements MONTREAL, QUEBEC -- 11/25/09 --
Pixman Nomadic Media Inc. (TSX VENTURE: PMN) ("Pixman" or the "Corporation") updates on the delay in producing its annual audited financial statements, management discussion and analysis for the financial year ended ..
Sky Magazine Wins Gold Award for Best Custom Publication
MINNEAPOLIS, Nov. 25 /PRNewswire/ -- Sky magazine, the monthly lifestyle, business and travel publication of Delta Air Lines, was awarded the Gold Eddie for best custom publication, single issue, in the 2009 Folio Awards. Folio is the definitive source for industry tre...
Research and Markets: Economic Downturn Clouds Short-term Prospects for the EMEA Inbound Contact Routing Systems Markets, but its Strong Fundamentals will Drive Growth in 2010 and Beyond DUBLIN -
Research and Markets (
Simply Hired Encourages Employers to Optimize Online Job Content
New SEO and Social Media Guide Provides Strategies to Create Unique, Useful, "Findable" Postings for Job Seekers/I/P
PMountain View, CA (PRWEB) November 16, 2009 -- In an effort to help employers to improve their job listing visibility and more effectively recruit qualified ca...
Stans Energy Corp. Announces an Increase of the Previously Announced Non Brokered Private Placement Offering TORONTO, ONTARIO -- 11/25/09 --
Stans Energy Corp. ("Stans" or the "Company") (TSX VENTURE: RUU) - STANS ENERGY CORP. ANNOUNCES AN INCREASE OF THE PREVIOUSLY ANNOUNCED NON BROKERED PRIVATE PLACEMENT OFFERING DATED November 10 2009 TO $1,000,000 USD..
Beezag Raises $3500 for Charity During the 2009 GBK Pre-American Music Awards Gift Lounge
NEW YORK, Nov. 25 /PRNewswire/ -- At GBK Productions' American Music Awards (AMA) Gifting Lounge, celebrities were not just receiving luxury items but also had the opportunity to give back to charity. This past Friday and Saturday (November 20th & 21st) in h...
Finally, Fashionable Functional Luggage For Women-Just In Time For Holiday Travel
NEW YORK, Nov. 25 /PRNewswire/ -- Until now, women had to choose functional luggage designed for men or fashionable luggage that was awkward to use. Now, with luggage from Diane von Furstenberg and Liz Claiborne travel can be fashionable, functional and fabulous. Just in time for holida...
|
|
|
|
|
|
|
|
|